[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Breaking: $RZLT's price target raised to $XX from $XX with a Buy rating reiterated by JonesTrading. Investor KOL event reveals a doubling of the addressable market for hyperinsulinism treatment.
This topic pertains to the performance and user engagement metrics of a digital platform, specifically focusing on the cryptocurrency $RZLT.
Engagements 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: XX
X Week: XXX +61,400%
X Month: XXXXX +3,834%
1-Year High: XXX on 2025-12-09
1-Year Low: X on 2025-11-14
Engagements by network (24h): X: X
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: X +300%
X Month: X +300%
1-Year High: X on 2025-12-12
1-Year Low: X on 2025-11-14
Mentions by network (24h): X: X
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $rzlts in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
X Week: X +200%
X Month: X +200%
1-Year High: X on 2025-12-12
1-Year Low: X on 2025-11-14
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"JonesTrading $RZLT's PT to $XX from $XX and reiterated at a Buy rating. $ZLDPF $CRNX AMLX JonesTrading said in its note: Rezolute hosted an investor KOL event to update the Street on ersodetug's market opportunity in hyperinsulinism (presentation). With topline Ph3 data in CHI coming in December much of the investor questions have now shifted to the market opportunity. On the call KOL insights suggest that there are 3000 initially addressable Tumor HI patients (prev. estimate was 1500). For CHI we have always maintained that the addressable market will include both patients who are responsive"
X Link @Quantumup1 2025-11-12T13:14Z 3936 followers, 1478 engagements